IP Library Patent Application 10977537
Patent Application
App. No. 10/977,537

Methods and compositions for inhibiting the function of polynucleotide sequences

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
10/977,537
Abstract

A therapeutic composition for inhibiting the function of a target polynucleotide sequence in a mammalian cell includes an agent that provides to a mammalian cell an at least partially double-stranded RNA molecule comprising a polynucleotide sequence of at least about 200 nucleotides in length, said polynucleotide sequence being substantially homologous to a target polynucleotide sequence. This RNA molecule desirably does not produce a functional protein. The agents useful in the composition can be RNA molecules made by enzymatic synthetic methods or chemical synthetic methods in vitro; or made in recombinant cultures of microorganisms and isolated therefrom, or alternatively, can be capable of generating the desired RNA molecule in vivo after delivery to the mammalian cell. In methods of treatment of prophylaxis of virus infections, other pathogenic infections or certain cancers, these compositions are administered in amounts effective to reduce or inhibit the function of the target polynucleotide sequence, which can be of pathogenic origin or produced in response to a tumor or other cancer, among other sources.

Claims (36)

1 - 67 . (canceled)

68 . A method for inhibiting the growth of a pathogen comprising contacting the pathogen with a double-stranded RNA (dsRNA) molecule that corresponds to a target gene essential to growth of the pathogen; and incubating said dsRNA molecule and said pathogen under conditions suitable for RNA interference, thereby inhibiting the growth of said pathogen.

69 . The method of claim 68 , wherein said pathogen is contained in a cell.

70 . The method of claim 69 , wherein said pathogen is contacted in vivo.

71 . The method of claim 68 , wherein said pathogen is a virus.

72 . The method of claim 71 , wherein said virus is a retrovirus.

73 . The method of claim 72 , wherein said retrovirus is HIV.

74 . The method of claim 70 , wherein said pathogen causes a disease upon infecting an organism.

75 . The method of claim 74 , wherein said organism is a mammal.

76 . The method of claim 69 , wherein said target gene is a cellular gene.

77 . The method of claim 71 , wherein said target gene is a viral gene.

78 . The method of claim 73 , wherein said target gene is an HIV gene.

79 . The method of claim 78 , wherein said HIV gene is gag, pol or env.

80 . The method of claim 69 , wherein said contacting is by a method selected from the group consisting of transfection and viral infection.

81 . The method of claim 68 , wherein said dsRNA is encoded by a viral vector.

82 . A composition comprising dsRNA that corresponds to a target gene of the HIV genome.

83 . The composition of claim 82 , wherein said target gene is selected from the group consisting of gag, pol and env.

84 . The composition of claim 83 , wherein said target gene is gag.

85 . The composition of claim 83 , wherein said target gene is pol.

86 . A method for identifying a gene sequence that is a target for RNA interference aimed at inhibiting the growth of a pathogen, said method comprising the steps of: (a) selecting a candidate target gene sequence; (b) contacting a host cell containing a pathogen with a dsRNA that corresponds to the target gene sequence; and (c) determining whether the dsRNA inhibits the growth of said pathogen.

87 . The method of claim 86 , wherein said pathogen is a virus.

88 . The method of claim 87 , wherein said virus causes a disease in mammals.

89 . The method of claim 86 , wherein said target gene sequence is cellular.

90 . The method of claim 87 , wherein said target gene sequence is viral.

91 . The method of claim 86 , wherein said contacting occurs by a method selected from the group consisting of transfection and viral infection.

92 . The method of claim 86 , wherein said dsRNA is contained on a viral vector.

93 . A method for inhibiting the growth of a pathogen in an organism, comprising administering to the organism a double-stranded RNA (dsRNA) molecule that corresponds to a target gene, wherein said target gene is essential to growth of the pathogen.

94 . The method of claim 93 , wherein said organism is a mammal.

95 . The method of claim 94 , wherein said mammal is human.

96 . A method of treating a pathogenic condition in a host organism, said method comprising the steps of: (a) identifying the pathogen causing the condition; (b) determining a suitable target gene sequence for RNA interference that is aimed at inhibiting the growth of the pathogen; and (c) contacting said organism with a dsRNA sequence that corresponds to said target gene sequence under conditions suitable for RNA interference, thereby treating the pathogenic condition.

97 . The method of claim 96 , wherein said target gene corresponds to a host cellular gene.

98 . The method of claim 96 , wherein said target gene corresponds to a pathogen gene.

99 . The method of claim 96 , wherein said pathogen is a virus.

100 . The method of claim 96 , wherein said contacting is effected with a viral vector.

101 . The method of claim 96 , wherein said host organism is a mammal.

102 . The method of claim 101 , wherein said mammal is human.

Assignments (2)
RELEASE OF SECURITY INTEREST Recorded Dec 5, 2008
From: NEW ENTERPRISE ASSOCIATES 10, LIMITED PARTNERSHIP; BURRILL LIFE SCIENCES CAPITAL FUND, L.P.; BURRILL INDIANA LIFE SCIENCES CAPITAL FUND, L.P.; OFCO CLUB IV; HEALTHCAP IV KB; HEALTHCAP IV, L.P.; HEALTHCAP IV BIS, L.P.; S.R. ONE, LIMITED; QUAKER BIOVENTURES, L.P.; QUAKER BIOVENTURES TOBACCO FUND, L.P.; POSCO BIOVENTURES I, L.P.
To: NUCLEONICS, INC.
Reel/Frame 021932/0001 →
SECURITY AGREEMENT Recorded Sep 29, 2008
From: NUCLEONICS, INC.
To: NEW ENTERPRISE ASSOCIATES 10, LIMITED PARTNERSHIP; S.R. ONE, LIMITED; OFCO CLUB IV; HEALTHCAP IV KB; HEALTHCAP IV, L.P.; HEALTHCAP IV BIS, L.P.; BURRILL LIFE SCIENCES CAPITAL FUND, L.P.; BURRILL INDIANA LIFE SCIENCES CAPITAL FUND, L.P.; QUAKER BIOVENTURES, L.P.; QUAKER BIOVENTURES TOBACCO FUND, L.P.; POSCO BIOVENTURES I, L.P.
Reel/Frame 021602/0423 →